5-HT3 RECEPTOR MODULATOR, THE CRYSTALLINE FORM, METHODS OF MAKING, AND USE THEREOF
The present disclosure discloses free form or base and salts of compound of formula (I). Said salts include adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate or L-pyroglutamate. The present disclosure also discloses the crystals of free form and above salts.
1 . A salt of the molecule with the following formula (I)
2 . A salt according to claim 1 , wherein the salt is one or more of the adipate, benzenesulphonate, hydrobromide, fumarate, benzoate, methanesulfonate, L-malate, d-glyconate, sorbate, phosphate, sulfate, L-tartrate, p-methylbenzenesulphonate, citrate, hydrochloride, ethanesulfonate, 1-hydroxy-2-naphthoate, succinate, acetate, glutarate, or L-pyroglutamate salt.
3 . A salt according to claim 2 , wherein the salt is one or more of the methanesulfonate, phosphate, hydrochloride, succinate, 1-hydroxy-2-naphthoate, or L-pyroglutamate salt.
4 . A salt according to claim 3 , which comprises the methanesulfonate salt.
5 . A salt according to claim 4 characterized substantially by at least one of the following powder x-ray diffraction pattern peaks expressed in terms of diffraction angle 2θ (±0.2°) as measured with copper Kα radiation chosen from: 10.2°, 12.9°, and 23.9°.
6 . A salt according to claim 3 , which comprises the phosphate salt.
7 . A salt according to claim 6 characterized substantially by at least one of the following powder x-ray diffraction pattern peaks expressed in terms of diffraction angle 2θ (±0.2°) as measured with copper Kα radiation chosen from: 9.7°, 12.3°, 20.1°, and 21.3°.
8 . A salt according to claim 3 , which comprises the hydrochloride salt.
9 . A salt according to claim 8 characterized substantially by at least one of the following powder x-ray diffraction pattern peaks expressed in terms of diffraction angle 2θ (±0.2°) as measured with copper Kα radiation chosen from: 17.7°, 21.5°, and 22.3°.
10 . A salt according to claim 3 , which comprises the succinate salt.
11 . A salt according to claim 10 characterized substantially by at least one of the following powder x-ray diffraction pattern peaks expressed in terms of diffraction angle 2θ (±0.2°) as measured with copper Kα radiation chosen from: 4.3°, 20.1°, and 22.7°.
12 . A salt according to claim 3 , which comprises the 1-hydroxy-2-naphthoate salt.
13 . A salt according to claim 12 characterized substantially by at least one of the following powder x-ray diffraction pattern peaks expressed in terms of diffraction angle 2θ (±0.2°) as measured with copper Kα radiation chosen from: 6.5°, 10.7°, 19.2°, and 20.5°.
14 . A salt according to claim 3 , which comprises L-pyroglutamate salt.
15 . A salt according to claim 14 characterized substantially by at least one of the following powder x-ray diffraction pattern peaks expressed in terms of diffraction angle (2θ) (±0.2°) as measured with copper Kα radiation chosen from: 5.5°, 16.8°, and 22.4°.
16 . A polymorph of a compound having the structure represented by formula (I)
17 . The polymorph of claim 16 , which is characterized substantially by at least one of the following powder x-ray diffraction pattern peak expressed in terms of diffraction angles (2θ) (±0.2°) as measured with copper Kα radiation chosen from: 11.3°, 14.6°, 21.8° and 23.6°.
18 . A pharmaceutical formulation comprising a salt or a polymorph of a compound having a structure represented by formula (I), as defined in claim 16 , and a pharmaceutically acceptable excipient.
19 . A method of treating a disease, comprising administering to a subject in need of such treatment a therapeutically effective amount of a salt or a polymorph of a compound having a structure represented by formula (I), as defined in claim 16 .
20 . The method according to claim 19 , wherein the disease comprises inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, drug/toxin-induced cognitive impairment (e.g., from alcohol, barbiturates, vitamin deficiencies, recreational drugs, lead, arsenic, mercury), disease-induced cognitive impairment (e.g., arising from Alzheimer's disease (senile dementia), vascular dementia, Parkinson's disease, multiple sclerosis, AIDS, encephalitis, trauma, renal and hepatic encephalopathy, hypothyroidism, Pick's disease, Korsakoffs syndrome and frontal and subcortical dementia), hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supramuscular palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome.